P63 Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma
| Autor: | Marciniak, A., Gultyaev, D., Orbzut, G., Mollon, P., Wallace, J.F. |
|---|---|
| Zdroj: | In Value in Health July 2022 25(7) Supplement:S300-S301 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect